```html

Jaccoud Arthritis – A Complete Patient‑Friendly Guide

Overview

Jaccoud arthritis (JA) is a chronic, non‑erosive, deforming arthritis that most often involves the hands, wrists, and feet. Unlike rheumatoid arthritis, the joint damage seen on X‑ray is minimal, but the deformities (e.g., “swan‑neck” or “boutonnière” fingers) are striking and usually reversible with treatment.

• Who it affects: Primarily adults aged 30–60, with a strong female predominance (≈ 2–3 : 1 women : men). It is most commonly linked to systemic autoimmune disorders, especially systemic lupus erythematosus (SLE).
• Prevalence: Exact worldwide prevalence is unknown because JA is rare and often misdiagnosed. In SLE cohorts, JA occurs in ~10‑20 % of patients, making it one of the more frequent musculoskeletal manifestations of lupus <sup>1</sup>.
• Geography: Reported worldwide, with slightly higher recognition in tertiary rheumatology centers in North America and Europe.

Symptoms

The clinical picture of JA can vary, but the following features are typical. Symptoms often develop gradually over months to years.

Joint‑related symptoms

• Pain or ache: Usually mild to moderate, worsens with activity and improves with rest.
• Swelling: Soft, non‑tender swelling of the peri‑articular tissue (soft‑tissue swelling) rather than true effusion.
• Stiffness: Morning stiffness lasting <30 minutes in most cases (shorter than the >1 hour typical for rheumatoid arthritis).
• Deformities:
  • Ulnar deviation of the fingers.
  • Swan‑neck or boutonnière deformities.
  • “Z‑thumb” or “Mallet” thumb.
  • Reversible subluxations of the metacarpophalangeal (MCP) joints.
• Limited range of motion: Particularly in the MCP and wrist joints.

Systemic symptoms (when JA is secondary to another disease)

• Fatigue, fever, weight loss (common in lupus‑associated JA).
• Skin rash, oral ulcers, photosensitivity (if associated with SLE).
• Kidney, cardiac, or neurologic involvement – signs that point to an underlying systemic disease rather than isolated JA.

Causes and Risk Factors

Jaccoud arthritis is not a single disease; it is a pattern of joint injury that arises secondary to several underlying conditions.

Primary (idiopathic) JA

• Rare; no identifiable systemic disease.
• Thought to involve immune‑mediated synovial inflammation causing ligamentous laxity without bone erosion.

Secondary JA – most common

• Systemic lupus erythematosus (SLE): The leading association, especially in women of childbearing age.
• Rheumatic fever: Historically common; still seen in low‑resource settings.
• Other connective‑tissue diseases: Sjögren’s syndrome, mixed connective‑tissue disease, scleroderma.
• Infections: Chronic bacterial endocarditis, Chagas disease.
• Hematologic disorders: Chronic lymphocytic leukemia, multiple myeloma (rare).

Risk factors

• Female sex.
• Presence of an underlying autoimmune disease (especially SLE).
• Genetic predisposition to autoimmunity (family history of lupus, rheumatoid arthritis, or other rheumatic illnesses).
• Environmental triggers that can precipitate autoimmunity – e.g., smoking, ultraviolet light exposure in lupus‑prone individuals.

Diagnosis

Diagnosis rests on a combination of clinical assessment, imaging, and exclusion of other erosive arthritides.

Clinical evaluation

• Detailed history – onset, pattern of joint involvement, associated systemic symptoms.
• Physical exam – look for characteristic deformities that are reducible (i.e., they improve when the hand is passively straightened).

Laboratory tests

• Autoantibody panel: ANA, anti‑dsDNA, anti‑Sm (to assess for SLE); rheumatoid factor (RF) and anti‑CCP are usually negative in pure JA.
• Complete blood count, ESR, CRP – to gauge inflammation.
• Complement levels (C3, C4) – often low in active lupus.

Imaging

• Plain radiographs: Show soft‑tissue swelling and joint subluxation but no erosions or joint space narrowing – the hallmark that distinguishes JA from rheumatoid arthritis.
• Ultrasound: Detects synovial hypertrophy and effusion; helpful for guiding intra‑articular injections.
• MRI (rarely needed): Provides detailed view of ligamentous laxity and excludes other pathologies.

Diagnostic criteria (simplified)

Most rheumatologists use the following practical rule‑of‑thumb:

1. Reversible hand/wrist deformities without radiographic erosions.
2. Presence of a known associated systemic disease (or idiopathic if none found).
3. Exclusion of other erosive arthritides (e.g., rheumatoid arthritis, psoriatic arthritis).

When these criteria are met, the diagnosis of Jaccoud arthritis is considered secure <sup>2</sup>.

Treatment Options

Because joint damage is not destructive, the treatment goal is to control inflammation, correct deformities, and preserve function.

Medications

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): First‑line for pain and mild inflammation (e.g., ibuprofen 400‑600 mg every 6–8 h). Use cautiously in patients with renal disease or cardiovascular risk.
• Low‑dose glucocorticoids: Prednisone 5–10 mg daily can rapidly reduce synovitis and improve deformity. Taper to the lowest effective dose to limit long‑term side effects.
• Disease‑modifying antirheumatic drugs (DMARDs):
  • Hydroxychloroquine – especially effective when JA is linked to SLE.
  • Azathioprine or Mycophenolate mofetil – for patients with refractory lupus‑related disease.
  • Traditional DMARDs such as methotrexate are less effective because the disease is non‑erosive, but they may be used if there is overlapping rheumatoid arthritis.
• Biologic agents: Limited data; case reports describe success with belimumab (anti‑BLyS) or rituximab in refractory lupus‑associated JA. Use only under specialist supervision.

Procedural interventions

• Intra‑articular corticosteroid injections: Provide rapid relief for isolated painful joints.
• Physical therapy & hand splinting: Night splints can maintain corrected positions and reduce deformity recurrence.
• Surgical options (rare):
  • Tendon transfer or reconstruction for severe, fixed deformities.
  • Synovectomy in cases of persistent synovitis unresponsive to medication.

Lifestyle and supportive measures

• Regular low‑impact exercise (e.g., swimming, walking) to keep joints mobile.
• Joint‑protective techniques – use larger joints for heavy tasks, avoid prolonged gripping.
• Balanced diet rich in omega‑3 fatty acids (fish, flaxseed) can modestly reduce systemic inflammation.
• Smoking cessation – critical for patients with lupus or other autoimmune diseases.

Living with Jaccoud Arthritis

Most people with JA maintain a good quality of life when the condition is recognized early and managed proactively.

Daily management tips

• Hand exercises: Finger stretch and glide exercises 3‑4 times daily (e.g., “finger spread” and “piano” movements).
• Ergonomic adaptations: Use padded grips on tools, jar openers, and keyboard supports.
• Temperature awareness: Cold can increase joint stiffness; keep hands warm with gloves or warm water soaks.
• Medication adherence: Keep a medication diary; set alarms to avoid missed doses.
• Regular follow‑up: Rheumatology visits every 3–6 months, or sooner if symptoms change.
• Psychosocial support: Join patient groups for lupus or connective‑tissue disease – sharing experiences reduces anxiety and improves coping.

Prevention

Because JA is largely secondary to other diseases, “prevention” focuses on minimizing the risk or severity of those underlying conditions.

• Early detection and treatment of SLE or rheumatic fever dramatically lower the chance of developing JA.
• Adopt sun‑protective habits (broad‑spectrum sunscreen, protective clothing) to reduce lupus flares.
• Vaccinations (influenza, pneumococcal, COVID‑19) to prevent infections that can trigger systemic inflammation.
• Maintain a healthy weight and stay physically active to reduce systemic inflammatory load.

Complications

If left untreated or poorly controlled, Jaccoud arthritis may lead to:

• Fixed deformities: Chronic subluxations can become permanent, impairing hand function.
• Functional disability: Difficulty performing fine motor tasks (buttoning, typing, writing).
• Secondary osteoarthritis: Abnormal joint mechanics increase wear over time.
• Psychological impact: Chronic pain and loss of independence can lead to depression or anxiety.
• Complications of systemic disease: In lupus‑related JA, renal, cardiac, or neuro‑psychiatric involvement may be life‑threatening if the underlying disease is uncontrolled.

When to Seek Emergency Care

---

<sup>1</sup> Petri M, et al. *Systemic Lupus Erythematosus*. Nat Rev Dis Primers. 2020;6:130. <sup>2</sup> Jaccoud B. “A New Form of Chronic Arthritis.” *Rev Med Suisse*. 1869;10:118‑122. Additional sources: Mayo Clinic, CDC, NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases, WHO.

```